These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 35883176)

  • 1. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
    Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
    ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy.
    Mao L; Ma P; Luo X; Cheng H; Wang Z; Ye E; Loh XJ; Wu YL; Li Z
    ACS Nano; 2023 Jun; 17(11):9826-9849. PubMed ID: 37207347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
    Yin Q; Wang Y; Xiang Y; Xu F
    Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG-Based Nanovaccines for Cancer Immunotherapy.
    Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
    Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
    Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
    ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-adjuvanting polymeric nanovaccines enhance IFN production and cytotoxic T cell response.
    Zhao M; He C; Zheng X; Jiang M; Xie Z; Wei H; Zhang S; Lin Y; Zhang J; Sun X
    J Control Release; 2024 May; 369():556-572. PubMed ID: 38580136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.
    Xu F; Yuan Y; Wang Y; Yin Q
    Biomed Pharmacother; 2023 Feb; 158():114117. PubMed ID: 36528914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
    Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
    Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
    Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
    Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.